• Publications
  • Influence
Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement
TLDR
The heterozygous CYP2C9 and VKORC1 genotypes influence warfarin dosing in an early phase as well as steady state of warFarin therapy in Korean patients with mechanical heart valve replacement.
Effect of HNF4&agr; genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals
TLDR
This study showed HNF4&agr; G60D to be an independent predictor for increased AUC0–∞, C max of tolterodine and increased A UC0-∞ of the active moiety (tolterodines+5-hydroxymethyl-tolerodine) and a significant proportion of the variance in these parameters was explained together by CYP2D6 and HNF3D6 genotypes.
The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil
TLDR
CYP3A5 and CYP3A4 play a significant role in the metabolism of PDE5Is, especially sildenafil and udenafil, and vardenafil.
The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
AIM The primary objective of the present study was to evaluate the pharmacokinetic and pharmacodynamic interactions between clopidogrel and cilostazol in relation to the CYP2C19 and CYP3A5 genotypes.
Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
TLDR
Co-administration of metformin and voglibose had no statistically or clinically significant effects on the pharmacokinetics of met formin in healthy subjects.
The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype
TLDR
The results suggest that the disposition of these PDE5Is are differently influenced by the CYP3A5*3 genotype of individual participants, which may lead to the clinical response variation.
The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration
TLDR
Delayed time to reach maximal IPA as well as decreased IPA may influence the increased risk of the acute cardiac events in CYP2C19 PM and IM.
CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina
TLDR
CYP2C19 poor metabolizer is associated with poor clinical outcome of clopidogrel therapy in Asian patients with AMI but not in those with stable angina possibly because of differential requirement of platelet suppression in patients with acute myocardial infarction and stableAngina.
Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15‐0444)
TLDR
Pharmacokinetics of gemigliptin was comparable between HD and non‐HD periods in ESRD patients and no dose adjustment in patients with RI is proposed on the basis of exposure–response relationship.
Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System
TLDR
Evaluating the cost effectiveness of genotype-guided warfarin dosing in patients with MHVR under the FFS system from the Korea healthcare sector perspective found that it was cost effective compared with only standard warFarin therapy.
...
...